GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HeXun Biosciences Co Ltd (ROCO:6986) » Definitions » ROCE %

HeXun Biosciences Co (ROCO:6986) ROCE % : 27.75% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is HeXun Biosciences Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HeXun Biosciences Co's annualized ROCE % for the quarter that ended in Jun. 2024 was 27.75%.


HeXun Biosciences Co ROCE % Historical Data

The historical data trend for HeXun Biosciences Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeXun Biosciences Co ROCE % Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROCE %
- -15.30 -1.06 7.64

HeXun Biosciences Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROCE % Get a 7-Day Free Trial -7.82 3.99 -5.68 18.44 27.75

HeXun Biosciences Co ROCE % Calculation

HeXun Biosciences Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=35.343/( ( (404.152 - 20.028) + (571.429 - 30.17) )/ 2 )
=35.343/( (384.124+541.259)/ 2 )
=35.343/462.6915
=7.64 %

HeXun Biosciences Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=155.856/( ( (571.429 - 30.17) + (612.974 - 30.854) )/ 2 )
=155.856/( ( 541.259 + 582.12 )/ 2 )
=155.856/561.6895
=27.75 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeXun Biosciences Co  (ROCO:6986) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


HeXun Biosciences Co ROCE % Related Terms

Thank you for viewing the detailed overview of HeXun Biosciences Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


HeXun Biosciences Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.

HeXun Biosciences Co Headlines

No Headlines